EUVIMEDSkopri EUVIMED
CrossrefKarta ta’ informazzjoni

Plasma adrenomedullin and response to erenumab in migraine: a REFORM study

Haidar M Al-Khazali, William Kristian Karlsson, Rune H Christensen, Rogelio Dominguez-Moreno, Messoud Ashina, Kristian A Haanes, Håkan Ashina

Brain Communications · 2026-11-10

DOI: 10.1093/braincomms/fcag433 ↗
AstrattDettalji biblijografiċi

Astratt

Abstract Adrenomedullin has been implicated in migraine pathogenesis and is structurally related to calcitonin gene–related peptide. However, it remains unknown whether circulating adrenomedullin reflects migraine biology or identifies patients most likely to benefit from calcitonin gene–related peptide-receptor blockade. We examined whether plasma adrenomedullin levels predict or reflect the clinical effects of erenumab for migraine prevention. In this prospective, single-centre biomarker study within the Registry for Migraine program, adults with episodic or chronic migraine received erenumab 140 mg every 4 weeks for 24 weeks, followed by 24 weeks of post-treatment follow-up. Plasma adrenomedullin concentrations were measured at baseline, Week 24, and Week 48 using a validated immunoluminometric assay. Co-primary outcomes were the association between baseline plasma adrenomedullin and either a ≥50% reduction in monthly migraine days or the absolute change in monthly migraine days from baseline to Weeks 13–24. Secondary analyses compared plasma adrenomedullin across responders, non-responders, and healthy controls and assessed longitudinal changes. A total of 632 participants with migraine (mean age 44.1 ± 12.3 years; 90.2% female; 61.2% chronic migraine) contributed at least one plasma sample, and 147 healthy controls were included as a matched reference group. Among 539 participants with evaluable response data, 276 (51.2%) were responders. Baseline plasma adrenomedullin was not associated with a ≥50% reduction in monthly migraine days (OR, 1.00; 95% CI, 0.99 to 1.03; P = 0.60) or absolute monthly migraine days reduction (β, 0.052 days per pg/mL; 95% CI, −0.002 to 0.106; P = 0.06). Plasma adrenomedullin concentrations did not differ between responders and non-responders at any time point and were similar between participants with migraine and healthy controls. Concentrations remained stable during treatment and were not correlated with changes in headache frequency or severity. Sensitivity analyses confirmed the primary findings. Plasma adrenomedullin neither predicted nor reflected clinical response to erenumab in adults with migraine. These findings suggest that circulating adrenomedullin is unlikely to serve as a clinically useful biomarker for treatment selection or disease monitoring in migraine.

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.

Ara t-tariffi →